<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31291846</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study.</ArticleTitle><Pagination><StartPage>1091</StartPage><EndPage>1100</EndPage><MedlinePgn>1091-1100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0961203319860582</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The study aimed to investigate whether HLA-G antigen is expressed in the kidneys of patients affected by lupus nephritis (LN) and whether its detection in renal biopsies could be adopted as a marker of treatment response and prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty renal biopsies from patients with LN were selected and analyzed through immunohistochemistry. Laboratory and clinical data were retrospectively collected at baseline, 6 and 12 months and at the latest clinical appointment. A number of patients (63.3%) were treated with rituximab (RTX) +/- methylprednisolone in the induction phase. The expression of HLA-G in glomeruli, tubules and infiltrating cells was examined and compared between lupus patients who achieved either complete or partial renal response and those who did not respond to treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">HLA-G staining was observed in the glomeruli of 20 of 30 samples from patients with LN. The expression of the antigen was detected in podocytes, along glomerular capillary walls, on parietal glomerular epithelial cells and within the juxtaglomerular apparatus. Seventy per cent of patients whose glomeruli expressed HLA-G achieved partial or complete response at 6 months and 75% at the latest available follow up compared with 30% and 40%, respectively, of those who did not show any expression. The pattern of staining in tubules and infiltrating cells was highly variable precluding any clinical correlation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates that HLA-G is expressed in renal tissue in LN. Our retrospective data suggest that its expression could correlate with response to treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foschi</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortolotti</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>3 Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>A F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratigou</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>4 Department of Pathology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>5 Section of Pathology and Biomolecular Diagnostics, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padovan</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortoluzzi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lightstone</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>6 Section of Renal and Vascular Inflammation, Department of Medicine, Imperial College London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>7 Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>T D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>7 Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botto</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>T H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>R</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9507-9126</Identifier><AffiliationInfo><Affiliation>3 Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govoni</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>2 Centre for Complement and Inflammation Research, Imperial College London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>082291</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>098476</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059951">HLA-G Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059951" MajorTopicYN="N">HLA-G Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA-G</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">immunohistochemistry</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList><CoiStatement>
<b>CONFLICT OF INTEREST STATEMENT</b>
. L.L. has received grants and non-financial support from Roche, personal fees from Aurinia, GSK, Genentech and Medimmune, outside the submitted work. The other authors declare no conflict of interest in relation to the reported work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31291846</ArticleId><ArticleId IdType="mid">EMS127225</ArticleId><ArticleId IdType="pmc">PMC7611013</ArticleId><ArticleId IdType="doi">10.1177/0961203319860582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen J, Shen B, Jiang Y, et al. Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients. Clin Exp Med. 2013;13:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">22562117</ArticleId></ArticleIdList></Reference><Reference><Citation>Veit TD, Cordero EA, Mucenic T, et al. Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus. 2009;18:424&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">19318395</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio CR, Veit TD, Monticielo OA, et al. Association of the HLA-G gene +3142C&amp;gt;G polymorphism with systemic lupus erythematosus. Tissue Antigens. 2011;77:540&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">21395561</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsiv&#xe1;is-Urenda AE, Baranda L, Alvarez-Quiroga C, Abud-Mendoza C, Gonz&#xe1;lez-Amaro R. Expression and Functional Role of HLA-G in Immune Cells from Patients with Systemic Lupus Erythematosus. J Clin Immunol. 2011;31:369&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">21188486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo R, Hviid TV, Govoni M, et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens. 2008;71:520&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">18380776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosado S, Perez-Chacon G, Mellor-Pita S, et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol. 2008;69:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Bae SC, Song GG. Meta-analysis of associations between functional HLA-G polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2015;35:953&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">25326335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Bae SC. Association between a Functional HLA-G 14-bp Insertion/deletion Polymorphism and Susceptibility to Autoimmune Diseases: A Meta-analysis. Cell Mol Biol (Noisy-le-grand) 2015;61:24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26667769</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li S, Zhang Y, et al. Meta-analysis of the relationship between 14bp insertion/deletion polymorphism of HLA-G gene and susceptibility to systemic lupus erythematosus. Hum Immunol. 2014;75:1171&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">25454623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucena-Silva N, de Souza VS, Gomes RG, et al. HLA-G 3&#x2019; untranslated region polymorphisms are associated with systemic lupus erythematosus in 2 Brazilian populations. J Rheumatol. 2013;40:1104&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">23678155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis SA, Palmer LS, McMichael AJ. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA class I molecule. J Immunol. 1990;144:731&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">2295808</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Human Immunology. 2003;64:1039&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">14602233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallet V, Blaschitz A, Crisa L, et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol. 1999;11:889&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">10360962</ArticleId></ArticleIdList></Reference><Reference><Citation>Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood. 2004;104:3153&#x2013;3160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284117</ArticleId></ArticleIdList></Reference><Reference><Citation>Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFoxp3+ regulatory T cells. Stem Cells. 2008;26:212&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">17932417</ArticleId></ArticleIdList></Reference><Reference><Citation>Alegre E, Rizzo R, Bortolotti D, Fernandez-Land&#xe1;zuri S, Fainardi E, Gonz&#xe1;lez A. Some Basic Aspects of HLA-G Biology. J Immunol Res. 2014;2014:657625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000973</ArticleId><ArticleId IdType="pubmed">24818168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitani A, Geraghty D. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc natl acad sci usa. 1992;89:3947&#x2013;3951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC525608</ArticleId><ArticleId IdType="pubmed">1570318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni O, Mulay S, Darisipudi M, et al. Treatment with Human Leukocyte Antigen (HLA-G) attenuates progression of Lupus Nephritis in MRL-lpr mice. Nephrol Dial Transplant. 2013;28(Suppl 1):i42&#x2013;i43.</Citation></Reference><Reference><Citation>Li BL, Lin A, Zhang XJ, et al. Characterization of HLA-G expression in renal cell carcinoma. Tissue Antigens. 2009;74:213&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">19531101</ArticleId></ArticleIdList></Reference><Reference><Citation>Crispim JCO, Duarte RA, Soares CP, et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transplant Immunology. 2008;18:361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">18158124</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebmann V, da Silva Nardi F, Wagner B, Horn PA. HLA-G as a tolerogenic molecule in transplantation and pregnancy. J Immunol Res. 2014;2014:297073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131093</ArticleId><ArticleId IdType="pubmed">25143957</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampangi S, Wang X, Beagley KW, et al. Human proximal tubule epithelial cells modulate autologous B cell function. Nephrol Dial Transplant. 2015;30:1674&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">26058593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA. 2001;98:12150&#x2013;12155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59783</ArticleId><ArticleId IdType="pubmed">11572934</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186:1849&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124090</ArticleId><ArticleId IdType="pubmed">21187439</ArticleId></ArticleIdList></Reference><Reference><Citation>Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pubmed">23740227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez AS, Alegre E, LeMaoult J, Carosella E, Gonzalez A. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Molecular Immunology. 2006;43:2151&#x2013;2160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490253</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;gele H, Allam R, Pawar RD, Reichel CA, Krombach F, Anders HJ. Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway. Am J Pathol. 2009;175:1896&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774054</ArticleId><ArticleId IdType="pubmed">19834059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheshgiri R, Rao V, Tumiati LC, et al. Progesterone Induces Human Leukocyte Antigen-G Expression in Vascular Endothelial and Smooth Muscle Cells. Circulation. 2008;118:S58&#x2013;S64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18824770</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigg RJ. Complement and autoimmune glomerular diseases. Curr Dir Autoimmun. 2004;7:165&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">14719380</ArticleId></ArticleIdList></Reference><Reference><Citation>Coers W, Brouwer E, Vos JT, et al. Podocyte expression of MHC class I and II and intercellular adhesion molecule-1 (ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol. 1994;98:279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1534396</ArticleId><ArticleId IdType="pubmed">7955534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft SW, Schwartz MM, Korbet S Metal. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548564</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H, Chen S, He FF, Wang YM, Bondzie P, Zhang C. New Insights into Glomerular Parietal Epithelial Cell Activation and Its Signaling Pathways in Glomerular Diseases. Biomed Res Int. 2015;2015:318935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383425</ArticleId><ArticleId IdType="pubmed">25866774</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeets B, Moeller MJ. Parietal epithelial cells and podocytes in glomerular diseases. Seminars in Nephrology. 2012;32:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">22958490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagni L, Angelotti ML, Ronconi E, et al. Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem Cell. 2015;5:248&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618832</ArticleId><ArticleId IdType="pubmed">26235895</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng DG, Sunseri MW, Kaverina NV, Roeder SS, Pippin JW, Shankland SJ. Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int. 2015;88:999&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4654724</ArticleId><ArticleId IdType="pubmed">25993321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu M, Kondo S, Urushihara M, et al. Role of integrin-linked kinase in epithelial-mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant. 2006;21:2380&#x2013;2390.</Citation><ArticleIdList><ArticleId IdType="pubmed">16728424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics. 2003;55:63&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">12712263</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau P, Faure O, Lefebvre S, et al. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc. 2001;33:2277&#x2013;2280.</Citation><ArticleIdList><ArticleId IdType="pubmed">11377528</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo R, Rubini M, Govoni M, et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics. 2006;16:615&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">16906016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Liang J, Yao G, et al. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients. Int Immunopharmacol. 2017;44:234&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">28129605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>